Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeneGene 3 pediatric hemophilia B gene therapy study
2020-002443-38Phase 3
- Sponsor
- Pfizer
- Start
- Oct 2020
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fidanacogene elaparvovec in hemophilia B (HB), sponsored by Pfizer. Primary endpoint: Annualized bleeding rate.
02
Drugs
fidanacogene elaparvovec
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2020-002443-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002443-38.